187
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Clinical Value of Combined Multi-Indicator Tests in Diagnosis of Benign Ovarian

, , , , &
Pages 2047-2053 | Received 28 Feb 2023, Accepted 16 May 2023, Published online: 29 May 2023

References

  • Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):1–9. doi:10.1186/s13048-019-0503-7
  • Rao S, Smith DA, Guler E, et al. Past, present, and future of serum tumor markers in management of ovarian cancer: a guide for the radiologist. RadioGraphics. 2021;41(6):1839–1856. doi:10.1148/rg.2021210005
  • Li J, Bao R, Peng S, Zhang C. The molecular mechanism of ovarian granulosa cell tumors. J Ovarian Res. 2018;11(1):13. doi:10.1186/s13048-018-0384-1
  • Clendenen TV, Ge W, Koenig KL, et al. Breast cancer risk factors and circulating anti-Müllerian hormone concentration in healthy premenopausal women. J Clin Endocrinol Metab. 2021;106(11):e4542–e4553. doi:10.1210/clinem/dgab461
  • Cheung A, Shah S, Parker J, et al. Non-epithelial ovarian cancers: how much do we really know? Int J Environ Res Public Health. 2022;19(3):1106. doi:10.3390/ijerph19031106
  • Jeon JH, Park SY, Lee SR, Jeong K, Chung HW. Serum anti-Müllerian hormone levels before surgery in patients with ovarian endometriomas compared to other benign ovarian cysts. J Menopausal Med. 2015;21(3):142–148. doi:10.6118/jmm.2015.21.3.142
  • Wang H, Liu P, Xu H, Dai H. Early diagonosis of ovarian cancer: serum HE4, CA125 and ROMA model. Am J Transl Res. 2021;13(12):14141.
  • Guleria S, Jensen A, Toender A, Kjaer SK. Risk of epithelial ovarian cancer among women with benign ovarian tumors: a follow-up study. Cancer Causes Control. 2020;31(1):25–31. doi:10.1007/s10552-019-01245-4
  • Ren X, Zhang H, Cong H, et al. Diagnostic model of serum miR-193a-5p, HE4 and CA125 improves the diagnostic efficacy of epithelium ovarian cancer. Pathol Oncol Res. 2018;24(4):739–744. doi:10.1007/s12253-018-0392-x
  • Shah S, Cheung A, Kutka M, et al. Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health. 2022;19(13):8113. doi:10.3390/ijerph19138113
  • Buza N. Frozen section diagnosis of ovarian epithelial tumors: diagnostic pearls and pitfalls. Arch Pathol Lab Med. 2019;143(1):47–64. doi:10.5858/arpa.2018-0289-RA
  • von Wolff M, Roumet M, Stute P, Liebenthron J. Serum anti-Mullerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve. Maturitas. 2020;134:34–40. doi:10.1016/j.maturitas.2020.02.001
  • Buratini J, Dal Canto M, De Ponti E, et al. Maternal age affects the relationship of basal FSH and anti-Müllerian hormone concentrations with post-ICSI/IVF live birth. Reprod Biomed Online. 2021;42(4):748–756. doi:10.1016/j.rbmo.2020.12.005
  • Taniguchi F, Sakamoto Y, Yabuta Y, et al. Analysis of pregnancy outcome and decline of anti‐Müllerian hormone after laparoscopic cystectomy for ovarian endometriomas. J Obstetr Gynaecol Res. 2016;42(11):1534–1540. doi:10.1111/jog.13081
  • Moolhuijsen LM, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on assessing ovarian function. J Clin Endocrinol Metab. 2020;105(11):3361–3373. doi:10.1210/clinem/dgaa513
  • Ye X-P, Yang Y-Z, Sun X-X. A retrospective analysis of the effect of salpingectomy on serum antiMüllerian hormone level and ovarian reserve. Am J Obstet Gynecol. 2015;212(1):53. e51–53. e10. doi:10.1016/j.ajog.2014.07.027
  • Bachelot A. Polycystic ovarian syndrome: clinical and biological diagnosis. Paper presented at: Annales de Biologie Clinique; 2016.
  • Biggs WS, Marks ST. Diagnosis and management of adnexal masses. Am Fam Physician. 2016;93(8):676–681.
  • Gomes TA, Campos EA, Yoshida A, Sarian LO, Andrade L, Derchain SF. Preoperative differentiation of benign and malignant non-epithelial ovarian tumors: clinical features and tumor markers. Revista Brasileira de Ginecologia e Obstetrícia. 2020;42:555–561. doi:10.1055/s-0040-1712993
  • Lahlou N, Brun J. Ovarian tumor markers of presumed benign ovarian tumors. J Gynecol Obstet Biol Reprod. 2013;42(8):752–759. doi:10.1016/j.jgyn.2013.09.030
  • Zhang Y, Qiao C, Li L, Zhao X, Li Y. Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders. Afr Health Sci. 2014;14(4):913–918. doi:10.4314/ahs.v14i4.20
  • Boussios S, Attygalle A, Hazell S, et al. Malignant ovarian germ cell tumors in postmenopausal patients: the royal Marsden experience and literature review. Anticancer Res. 2015;35(12):6713–6722.
  • Park SY, Oh YT, Jung DC. Differentiation between borderline and benign ovarian tumors: combined analysis of MRI with tumor markers for large cystic masses (≥ 5 cm). Acta Radiol. 2016;57(5):633–639. doi:10.1177/0284185115597266